Histologically confirmed, new diagnosis of PTCL
COHORT D: Histologically confirmed diagnosis of melanoma
Histologically or cytologically confirmed diagnosis of metastatic medullary thyroid cancer
Histologically or cytologically confirmed diagnosis of melanoma.
Histologically or cytologically confirmed diagnosis of melanoma
Histologically confirmed diagnosis of GIST
histologically confirmed diagnosis of metastatic CRPC
Histologically or cytologically confirmed diagnosis of prostate cancer
Histologically confirmed diagnosis of one of the following:
Histologically confirmed diagnosis of cHL.
Histologically or cytologically confirmed diagnosis of early stage prostate cancer
Patients must have histologically confirmed new diagnosis of breast cancer
have a histologically confirmed diagnosis of ER+ breast cancer;
Histologically confirmed diagnosis of RCC
Have histologically or cytologically confirmed diagnosis of pancreatic carcinoma
Pathologically confirmed diagnosis of cancer
Histologically confirmed diagnosis of melanoma
Histologically confirmed diagnosis of cancer as per the cohort specifications
Histologically confirmed diagnosis of epithelial cancer; subject must have a measurable disease for enrollment consideration
Histologically confirmed diagnosis of invasive cervical cancer
Histologically confirmed diagnosis of chordoma or chondrosarcoma
Histologically confirmed diagnosis of prostate cancer.
Histologically confirmed diagnosis of HCC
Histologically confirmed diagnosis of a CD20+ B-cell malignancy;
Subjects with histologically confirmed diagnosis of recurrent germ cell tumor
On primary diagnosis, patients must have had histologically confirmed adenocarcinoma of the colon or rectum; metastasis or recurrence do not need to be histologically confirmed
Must have histologically confirmed diagnosis of MPNST
Patients with a histologically-confirmed diagnosis of melanoma who have imaging findings suggestive of 1 to 4 brain metastases
Patients with a histologically or cytologically confirmed diagnosis of breast cancer; patients must have metastatic HER2 positive (+) disease
Subject has a definitive histologically or cytologically confirmed diagnosis of HER2(-) metastatic breast cancer.
Histologically-confirmed disease
Histologically or cytologically confirmed diagnosis of pancreatic cancer.
Histologically confirmed diagnosis of DLBCL
Histologically confirmed diagnosis of FL or MCL according to WHO 2008
Confirmed diagnosis of HER2 positive disease
Histologically confirmed diagnosis of melanoma
Histologically or cytologically confirmed diagnosis of HCC
Confirmed diagnosis of HER2 positive disease
Histologically confirmed diagnosis of malignant melanoma.
Histologically or cytologically confirmed diagnosis of metastatic uveal melanoma (mUM)
Patients must have a histologically confirmed diagnosis of Ph+ ALL
Histologically confirmed diagnosis of FL grade 3b.
Histologically or cytologically confirmed diagnosis
Histologically confirmed diagnosis of melanoma
Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.
Histologically confirmed diagnosis of prostate cancer
Histologically confirmed diagnosis of classical HL
Histologically or cytologically confirmed diagnosis of CRC
Histologically confirmed:
Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer
Participants must have histologically or cytologically confirmed diagnosis of SCLC
Prior diagnosis of HCC confirmed histologically.
Histologically confirmed diagnosis of PTCL
Cytopathologically or histologically confirmed diagnosis of MM
Histologically confirmed diagnosis of conventional chondrosarcoma of any grade.
Histologically or cytologically confirmed diagnosis of mCRC
Histologically confirmed diagnosis of myeloma
Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM.
Histologically or cytologically confirmed diagnosis of prostate cancer
Have a confirmed diagnosis of cancer
Histologically confirmed cancer diagnosis
Histologically confirmed diagnosis for which an allogeneic transplant is utilized
Histologically and/or cytologically confirmed diagnosis of ER+/HER2- breast cancer
Must have a histologically confirmed cancer diagnosis
Have histologically confirmed cancer
Have a histologically-confirmed diagnosis of breast cancer
Histologically confirmed diagnosis of prostate cancer
Histologically confirmed:
